In search of a treatment for a rare bone cancer

December 11, 2013

Johns Hopkins researchers say that a drug approved to treat lung cancer substantially shrank tumors in mice that were caused by a rare form of bone cancer called chordoma.

Reporting in the journal PLOS ONE, the researchers say the finding offers hope to chordoma patients, who have no once surgery and radiation have been exhausted. There are no U.S. Food and Drug Administration-approved medications for the disease and, because its incidence is only one in 1 million, there is little financial incentive for pharmaceutical companies to develop or test drugs to treat them.

"The encouraging news is that this drug is already used in humans to treat ," says study leader Gary L. Gallia, M.D., Ph.D., an assistant professor of neurosurgery and oncology at the Johns Hopkins University School of Medicine.

Chordoma occurs at the base of the skull and in the bones of the spine. This cancer is thought to arise from remnants of the cartilage-like structure that serves as a scaffold for the formation of the spinal column. These so-called notochord cells normally persist after birth and are lodged inside the spine and skull. In rare cases, they become malignant tumors. The tumors are generally slow-growing but tend to recur, and their proximity to critical structures such as the spinal cord, cranial nerves and brain stem make them difficult to treat. Median survival time is seven years after diagnosis.

Since chordoma is so rare, few models have existed to even study it outside cells in a petri dish, says Gallia, who together with colleagues last year developed a of the disorder. The model was created by implanting human tumor tissue into a mouse.

The researchers began their drug studies by first examining the makeup of the tumor cells in their mouse model to determine what might be causing the cells to grow and divide uncontrolled. They saw that the epidermal growth factor receptor (EGFR) pathway was active and suspected that it played a critical role in the malignancy. Gallia and his colleagues tested two FDA-approved drugs known to inhibit EGFR and found that erlotinib was able to better slow the growth of chordoma than gefitinib.

They then tested erlotinib in mice transplanted with human chordoma tumors. After 37 days of treatment, the average tumor volume in the control group was more than three times larger than in those animals that were treated with erlotinib. Further research indicated that EGFR activation was significantly reduced.

"We hit our target," Gallia says. "It drastically reduced the growth of the tumors."

Gallia says he hopes his findings will lead to testing in chordoma patients. Although a controlled clinical trial would be ideal, he says it may be difficult to get funding to test treatments for such a rare disease.

Alternatively, he says he hopes erlotinib might be used in selected patients whose tumors are shown to have active EGFRs and who have run out of other treatment options.

Explore further: Potential new drug for some patients with treatment-resistant lung cancer

Related Stories

Potential new drug for some patients with treatment-resistant lung cancer

October 20, 2013
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, ...

The right combination: Overcoming drug resistance in cancer

June 1, 2012
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...

Molecular marker predicts patients most likely to benefit longest from two popular cancer drugs

September 5, 2013
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...

Study explains why drug may help more cancer patients

November 18, 2013
(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...

FDA approves new drug for advanced lung cancer

July 12, 2013
(HealthDay)—A new drug to treat advanced lung cancer has been approved by the U.S. Food and Drug Administration.

Common genetic pathway could be conduit to pediatric tumor treatment

November 7, 2013
Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.